Research on pancreatic cancer has revealed that the anticancer effects of oxymatrine may be attributed to the regulation of the Bcl-2 and inhibitors of apoptosis (IAP) families, the release of mitochondrial cytochrome c, and the activation of caspase-3 [229]. Here, CASP3 is linked to pancreatic neoplasm.